



Cosmetic Products marketed for Atopic Dermatitis in Portugal: Analysis of Claims and Labeling

Fernandes, Mariermys^{1*}, Gama, Ana Rita^{1,2}, Martinez de Oliveira, José^{1,2}, Palmeira de Oliveira, Ana^{1,2,3}, Palmeira de Oliveira, Rita^{1,2,3}

¹Faculty of Health Sciences, University of Beira Interior, Av. Infante D. Henrique, Covilhã, Portugal ²CICS-UBI Health Sciences Research Center, Faculty of Health Sciences, University of Beira Interior, Av. Infante D. Henrique, Covilhã, Portugal ³Labfit-HPRD Health Products Research and Development, Lda, Edifício UBIMEDICAL Estrada Municipal 506, 6200-284 Covilhã, Portugal

Introduction

Atopic Dermatitis (AD) is a chronic and inflammatory skin disease that causes itching, dryness, redness, and inflammation.

AD therapy aims to control symptoms, which includes adjuvant cosmetics products to improve skin hydration (1)(2).

and

Aim: Conduct a market study to analyze cosmetics products used in the adjuvant treatment of atopic dermatitis based on their labeling, formulation, and claims according to European Regulations(3)(4).

Methods

26 cosmetic products from 8 brands were analyzed and divided into two categories: 13 cleansing cosmetic products and 13 body care cosmetics.

The study was divided into two phases to collect information:

1st	INCI		
	Rinse-off products	Leave-in products	
	Surfactant	Hydratation	
		Perfume, extract of plant and vegetal oils, preservatives	

Labeling

labeling analyzed was the according to <u>European</u> Regulation (EC) No. 1223/2009 <u>(3)</u>.

Claims 2nd

Claims

Claims on product packaging and domains under <u>European</u> Regulation (EC) No. 665/2013, considering market positioning for atopic dermatitis(4).

Results



European Regulation (EC) no 1223/2009 of 30 November 2009 (3)

Rinse-off products

- Bioderma® meets The bath of oil formulation recommended without anionic surfactants;
- The Uriage® bath oil <u>has more anionic surfactants</u> in its composition;


Leave-in products

Only 7 out of 13 products combinations of moisturizing ingredients covering the three hydration mechanisms of action (emollient, humectant, and occlusive).

Global analysis (102 ingredients in common)

- The <u>Uriage® cream</u> had the most **preservatives**;
- 27% (n=7) of products contained the indication of "parfum" in the ingredient listing.

2009 relativo aos produtos cosméticos. 2022



- Bath Oil
- Shower gel/cream
- -Precautions (Uriage®)
- -Date of minimal durability (Aveeno® and ISDIN®) (PAO is displayed)
- · Cream
- -Precautions (A-Derma®, Avène®, Uriage®, SVR®) -Date of minimal durability (Aveeno® and ISDIN®) (PAO is displayed)
- Baume ————

-Precautions (A-Derma®, Avène®, La Roche Posay®, Uriage®, SVR®) -Date of minimal durability (A-Derma® and Avène®) (PAO is displayed)

European Regulation (EC) no 655/2013 of 10 July 2013 (4) Legal compliance Truthfulness Evidential support Honesty Fairness Informed decisionmaking

- ISDIN® Shower Gel and Cream (E2 and E3)had ingredients with a perfuming function despite claiming to be fragrance-free.
- Aveeno® Shower Gel (B2) Claims to be free of parabens in its composition.
- <u>SVR®</u> Bath Oil (H1) "Replaces all other products in the daily routine."

Meets the criteria (?) Not enough data O Some irregularities

Conclusions

- There are different products on the market to help improve the symptoms of atopic dermatitis and consequently improve the quality of life of patients
- Most products comply with the composition recommendations for the care of atopic skin (regarding to moisturizing actives).
- The presence of fragrance continues to be frequent, probably to improve consumer acceptance.
- Ultimately, the study provides valuable information for individuals with atopic dermatitis looking for cosmetic products to mitigate their symptoms.

References

(1)Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-60 (2) Frazier W, Bhardwaj N. Atopic Dermatitis: Diagnosis and Treatment. Am Fam Physician. 2020;101(10):590-8 (3) Europeia U. REGULAMENTO (CE) N.o 1223/2009 DO PARLAMENTO EUROPEU E DO CONSELHO de 30 de Novembro de

(4)REGULAMENTO (ÚE) N. o 655/2013 DA COMISSÃO de 10 de julho de 2013 que estabelece critérios comuns para justificação das alegações relativas a produtos cosméticos (Texto relevante para efeitos do EEE). 2013;9-12

Acknowledgments

This work was supported by "AqvaTOPIC - Desenvolvimento de gama de produtos cosméticos com água mineral natural das Termas de S. Pedro do Sul, vocacionados para a dermatite atópica" I&DT Project financially supported by Portugal 2020 Program (PT 2020) through theCompetitiveness and Internationalization Operational Program (POCI) and by the European Union through the European Regional Development Fund (FEDER), with the code POCI-01-0247-FEDER-070908. This work was developed within the scope of the CICS-UBI projects UIDB/00709/2020 and UIDP/00709/2020, financed by national funds through the Portuguese Foundation for Science and Technology/MCTES.







